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Abstract
Background: Weakness is the primary impairment in paediatric neuromuscular diseases, impacting gait and gait-
related functional activities in ambulant children affected by these rare and often degenerative diseases. Gait speed
is an indicator of health and disability, yet gait is a complex, multi-faceted activity. Using the International
Classification of Function, Health and Disability (ICF) model, assessment of gait and functional ambulation should
consider the impairments, activity limitations and participation restrictions due to disease, and factors related to the
environment and the individual person.
Methods: This narrative review involved a literature search of databases including Medline, Embase and Pubmed
from 1946 to October 2019. Inclusion criteria included assessments of gait, endurance and ambulatory function in
paediatric (0–18 years) neuromuscular diseases.
Results: Fifty-two papers were identified reporting assessments of gait speed, timed function, endurance and
ambulatory capacity, gait-related balance and qualitative descriptive assessments of gait function and effect of
disease on gait and gait-related activities. Gait speed is an indicator of disability and children with neuromuscular
disease walk slower than typically developing peers. Increasing disease severity and age were associated with
slower walking in children with Duchenne muscular dystrophy and Charcot-Marie-Tooth disease. The six-minute
walk test is used widely as a test of endurance and ambulatory capacity; six-minute walk distance was substantially
reduced across all paediatric neuromuscular diseases. Endurance and ambulatory capacity was more limited in
children with spinal muscular atrophy type 3, congenital muscular dystrophy and older boys with Duchenne
muscular dystrophy. Only a few papers considered normalisation of gait parameters accounting for the effect on
gait of height in heterogeneous groups of children and linear growth in longitudinal studies. Balance related to gait
was considered in five papers, mainly in children with Charcot-Marie-Tooth disease. There was limited investigation
of factors including distance requirements and terrain in children’s typical environments and personal factors
related to self-perception of disease effect on gait and gait-related function.
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Conclusion: Assessments of gait and functional ambulation are important considerations in documenting disease
progression and treatment efficacy in the clinical setting; and in clinical trials of disease-modifying agents and
physiotherapeutic interventions in paediatric neuromuscular diseases. There is a need for expert consensus on core
gait and functional ambulation assessments for use in clinical and research settings.
Keywords: Neuromuscular disease, Duchenne muscular dystrophy, Spinal muscular atrophy, Charcot-Marie-tooth
disease, Myopathy, Weakness, Paediatric, Gait, Functional ambulation, Assessment
Background
Neuromuscular diseases (NMD) include disorders affect-
ing the anterior horn cells, peripheral nerves, neuromus-
cular junction and muscles, are often progressive and
exhibit a wide range of impairment and disability in af-
fected individuals. Relatively rare, in children these dis-
eases include spinal muscular atrophy (SMA; 1 in 10–
11,000) [1], Charcot-Marie-Tooth disease (CMT; 1 in
2.5–10,000) [2] and Duchenne muscular dystrophy
(DMD; 1 in 3.5–10,0000) [3]. Gait and functional ambu-
lation are important markers of disease and disability in
paediatric NMD. It has been proposed that gait velocity
or self-selected walking speed is the 6th vital sign of hu-
man function and is a predictor of overall health and
disability [4, 5]. Yet, human gait is a complex activity
and gait speed alone does not reflect all contributing fac-
tors and influences on gait [4, 5]. Functional ambulation
relates gait function and speed to mobility-related activ-
ities of daily living in a person’s own environment [6].
Thus, the assessment of gait and functional ambulation
in paediatric NMD must take in to consideration the
many constructs that contribute to these complex tasks,
including individual impairments, the task required, and
the environment in which these are performed.
Weakness is the primary impairment in NMD, often
presenting in childhood and adversely affecting gait and
functional ambulation. Additionally, muscle tightness,
contracture, musculoskeletal deformities, poor standing
balance and reduced endurance, all arising from weakness,
affect functional ambulatory tasks such as standing and
walking. Patterns of weakness differ depending on the
NMD, some affecting more proximal muscles (e.g. DMD)
and others more distal muscles (e.g. CMT). For the major-
ity of NMD of childhood, disease is progressive leading to
increasing weakness and disability across the lifespan. The
degree of disability in childhood NMD is variable ranging
from children who are extremely weak and unable to sit
(e.g. SMA type 1) to those with milder weakness who re-
main ambulant, albeit with gait difficulties including foot
drop, poor balance and reduced gait speed (e.g. CMT,
SMA type 3 and ambulant boys with DMD).
Gait dysfunction has important implications for func-
tion in everyday life. Ambulant children with NMD,
commonly report problems with walking, poor balance,
frequent trips and falls, increased fatigue and difficulty
keeping up with peers [7–11]. In this context, it is useful
to consider the assessment of gait and functional ambu-
lation in ambulant children with NMD in terms of the
International Classification of Function, Health and Dis-
ability (ICF) [12] (Fig. 1). Gait speed is an indicator of
impairment. However, a clinically meaningful assess-
ment also needs to consider limitations to the child’s ac-
tivities, restrictions to participation, environmental and
intrinsic personal factors. Activity limitations may in-
clude difficulty walking longer distances; problems with
balance may affect steadiness and safety when walking;
and ambulatory performance may be affected by changes
in environmental conditions, for example walking over
uneven ground or up and down steps. The use of gait or
mobility aids will also affect function and low walking
confidence or fear of falling may restrict participation
opportunities. Assessments of functional ambulation
need to take into account all of these factors. There is
no recognised single assessment tool of functional am-
bulation that encompasses all factors. However, there
are several clinical assessments that collectively illustrate
the effect of disease and disability on gait and function
in children with NMD. The aim of this paper is to re-
view assessments of gait and functional ambulation in
paediatric NMD.
Method
This narrative review considered the literature relating to
gait and functional ambulation in children and adolescents
with neuromuscular disease. Literature was searched in
Ovid Medline, Embase and PubMed from 1946 up to and
including October 2019. Keywords and search terms in-
cluded gait, walk*, ambul*, locomotion, functional ambul*,
paed*, pediatr*, child*, adoles*, neuromuscular disease,
Duchenne and Becker muscular dystrophy, Charcot-
Marie-Tooth disease, peripheral neuropathy not diabetes,
spinal muscular atrophy, myopathy, Pompe, myotonic
dystrophy, collagen VI disorders, fascioscapulohumeral
dystrophy or FSHD. Only full-text human studies in Eng-
lish were considered (see Supplementary material for ex-
ample of search strategy). Additionally, hand searching of
reference lists and conference abstracts was undertaken to
ensure relevant publications were included. Exclusion
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criteria included studies of non-ambulant participants, pri-
mary studies of physical activity and activity monitoring
that did not include assessments of gait or functional am-
bulation, and studies comprised primarily of adults (aged
> 18 years).
Results and discussion
Studies included
Review of the literature resulted in 52 papers describing
gait and functional ambulation in over eight neuromus-
cular diseases of childhood including CMT (15 papers),
Becker and Duchenne muscular dystrophies (B/DMD)
(21 papers), SMA (7 papers), congenital myotonic dys-
trophy (CMD) (2 papers), fascioscapulohumeral dys-
trophy (FSHD) (1 paper), Pompe disease (1 paper),
collagen VI disorders (1 paper) and other mixed cohorts
(4 papers) (Table 1). Two papers were systematic reviews
of gait in CMT [18] and DMD [28]. Several papers de-
scribed the same or similar cohorts, either cross-sectional
and longitudinal studies [11, 16, 20, 21, 34, 35, 42] or a de-
scriptive papers of a randomised controlled trial (RCT)
[24, 25, 38, 39]. The median age of participants in the
studies was 9.0 years and sample sizes ranged from 4 to
520. Some studies included adult participants and were
included despite the lack of age-related sub-analysis [9, 10,
26, 36, 48–52, 56, 57, 60] or if there were no paediatric
studies in a specific disease [55].
Assessments of gait and functional ambulation
Several assessments of gait and functional ambulation in
paediatric NMD were identified and discussed in the lit-
erature. These included timed function tests, for ex-
ample the 10m walk and/or run test [62, 63], the six-
minute walk test (6MWT) [64] and 100 m timed test
[30]. Tests of dynamic balance in walking, including the
balance subset of the Bruininks-Oseretsky Test, 2nd edi-
tion (BOT-2) [65] and the timed up and go (TUG) [66],
were considered due to the impact of balance on gait
and function. If studies of gait or functional ambulation
included activity monitoring, these were reported as an
adjunct to specific assessments of gait, however we did
not specifically search for studies of activity monitoring
alone. We also included descriptive scales or question-
naires that characterised gait-related function, including
the Functional Mobility Scale (FMS) [67] and the Walk-
12 scale [68].
Fig. 1 Paediatric neuromuscular disease as it relates to the ICF – factors relating to gait and functional ambulation (bold)
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Gait speed
For this review we focused on gait speed in terms of its
clinical utility as an indicator of health and disability [4, 5].
Assessment of gait speed was diverse with a range of re-
ported methodologies including 3-D gait analysis, elec-
tronic walkway and timed distance. Typically, gait is
assessed at natural self-selected steady walking pace, how-
ever some studies reported gait speed as calculated from
the 10m walk/run, usually a fast walk or run test [27, 56].
Gait speed was described most often in studies of children
with CMT (ten of fifteen papers), a reflection of the use of
clinical gait analysis in preparation for orthopaedic surgery
for the management of foot deformities common in CMT
[11, 16, 18–21, 23–26]. Children with CMT walked more
slowly than their typically developing peers and a decline
in gait speed over time was evident when growth was
accounted for by normalising gait speed to height or leg
length [16]. Greater disability in children with CMT was
reflected in slower gait speed in more severely affected
children [19].
Younger boys (< 7 years) with DMD did not walk sig-
nificantly slower than their typically developing peers
[41, 45]. However, boys older than 8 years with DMD
were significantly slower than their peers, an indicator of
the relentless and degenerative muscle disease [8, 31].
The study by Doglio et al. (2011) was the only study to
normalise gait speed to height when comparing boys
with DMD to TD controls. Normalising gait parameters
is an important consideration for boys with DMD who
are typically treated with corticosteroids, of which
growth retardation is a known side-effect. Therefore,
steroid-treated boys with DMD tend to be smaller than
their age-matched, steroid naïve and non-affected peers
[69]. Normalisation to height and/or leg length is an im-
portant to factor when reporting gait speed in paediatric
populations [70, 71].
Gait speed was reported in two other studies in chil-
dren with CMD [53] and a mixed aged study of children
and adults with late-onset Pompe disease [56]. Whilst
neither study included unaffected controls, the reported
gait speed for both cohorts was considerably slower than
reported normative reference data [72].
Six-minute walk test
The 6MWT is a valid and reliable standardised test of
physical endurance in boys with DMD [38]. A test of
ambulatory capacity, the 6MWT measures distance
walked in six minutes. Developed from the American
Thoracic Society and FDA-approved 6MWT [64], the
test has been modified for children with NMD with the
addition of a safety chaser and standardised verbal en-
couragement [44]. The utility of the 6MWT in paediatric
NMD clinical research is evident with over half of
the studies included in this review reporting its use
[9–11, 14, 16, 17, 24, 25, 29, 32–35, 37–40, 42–44,
50–61] (Table 1). Typical walkway distances were re-
ported as 25 m however some studies used walkways
as short as 10 m [24, 25]. This may reduce distance
walked due to more frequent turns resulting in
greater time spent decelerating and less time at a fast
walking pace [73].
Six-minute walk distance (6MWD) is reduced in chil-
dren and adolescents with NMD when compared to typic-
ally developing controls or normative reference data. In
boys with DMD and children with SMA type 3 and CMT,
6MWD declines with increasing age, reflecting disease
progression and increasing disability [10, 16, 34, 35, 37,
39, 40]. Normalisation of 6MWD to height or leg length,
accounts for linear growth across age groups and in longi-
tudinal studies, and is an important factor when determin-
ing the effect of disease on function [16]. Burns and
colleagues (2009), demonstrated a trend to shorter
6MWD in older children [25]. In a further study over 12
months, normalisation of 6MWD accounting for growth
revealed a decline in ambulatory capacity in children with
CMT [16]. Genotype also affects ambulatory capacity in
the 6MWT; children with milder subtypes of CMT in a
large study of 520 participants, walked further than chil-
dren with more severe subtypes [17]. Deterioration in am-
bulatory capacity over time was also affected by genotype
in 80 boys with DMD [40]. Several studies have reported
rates of change, either minimally clinically important dif-
ference (MCID) or minimal detectable change (MDC) for
6MWD in different NMD including DMD (MCID 26.4–
31.7m; − 53.67 change over 12months) [37, 38], SMA (−
7.9 to − 9.7m over 12months) [10] and FSHD (MDC95
34.3m) [55]. Measures of rate of change, MCID or MCD
are useful for clinicians when comparing the ambulatory
function of the children in their own clinical practice.
Timed function tests – 10 m walk/run
The timed 10m walk/run is widely used to assess function
in NMD and is a sensitive measure of disease progression
in ambulant boys with DMD [62, 74, 75]. In clinical prac-
tice, the timed 10m walk/run is conducted as a fast walk
or run dependent on the abilities of the child. However, in
the literature there were differences noted between
whether the test was conducted as a timed walk [15, 41,
56, 57] or run, and earlier studies conducted the test over
30 ft or 9 m [46, 47]. Timed 10m walk/run was most often
reported in boys with DMD [27, 29, 36–39, 41–43, 46, 47]
reflecting its common use as a predictor of disease in
DMD and less frequently in studies of CMT, SMA, Pompe
and Collagen VI [11, 15, 50, 52, 56, 57]. Across all NMDs,
10m walk/run times were slower compared to controls or
reported normative reference ranges. Disease progression
in boys with DMD was demonstrated with several studies
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reporting slower speed over 10m in boys older than 7
years [36, 39, 42].
Other assessments
Assessments of balance, endurance and alternative dis-
tance and timed tests (100 m timed walk and two-
minute walk test) were reported less frequently. The bal-
ance subset of the Bruininks-Oseretsky Test of Motor
Proficiency, 2nd Ed (BOT-2, NCS Pearson, Upper Saddle
River, NJ, USA) is a ten-item standardised test of bal-
ance in standing and walking [65]. It is widely used in
paediatric CMT having been incorporated into the
disease-specific CMT Pediatric Scale (CMTPedS) [76].
Balance in children with CMT was significantly reduced
when compared to age- and gender-matched controls
and normative reference data [11, 13, 14]. However,
over 12 months’, balance did not significantly deterior-
ate, indicative of the relatively slow progression of
neuropathy in children with CMT [16]. Reduced bal-
ance (BOT-2) was associated with wider base of sup-
port and greater step-to-step variability in the gait of
children with CMT [11].
The TUG was reported in two studies and is a valid,
reliable and responsive measure of gait-related balance
in children with physical disabilities [50, 59, 77, 78]. It
measures the time taken to stand from a seated position,
walk 3 m, turn around and return to a seated position.
Dunaway and colleagues (2014) demonstrated an associ-
ation between the TUG, slower 10 m walk/run time and
shorter 6MWD in children with SMA type 3 [50]. In a
further study comparing older children with peripheral
neuropathies (PN) of mixed origin to younger boys with
DMD, TUG times were longer in the children with
mixed PN [59]. The authors attributed the difference be-
tween groups to the effects of distal versus proximal
weakness patterns, however it may have also been due to
the PN group being older and therefore likely to be
more affected by their disease. Both the BOT-2 and the
TUG are useful assessments of gait-related balance and
inform clinical interpretation of the effects of NMD on
gait and function.
Alternatives to the 6MWT were reported in two stud-
ies. Alfano and colleagues (2017) reported the develop-
ment and validation of a 100m timed test in boys with
DMD as an assessment of functional ambulatory per-
formance. Their study included the establishment of typ-
ically developing normative reference data [30]. Findings
from this study indicated that performance on the 100 m
timed test improved up to the age of 7 years before plat-
eauing and declining with increasing age [30]. This find-
ing is similar to the 10 m walk/run and the 6MWT in
boys with DMD and is reflective of disease progression
[36, 39, 40, 42]. A second study in children with mixed
NMD, reported a two-minute walk distance (2MWD)
derived from the two-minute mark of the standard
6MWT, and found a strong correlation between 2MWD
and 6MWD [58]. Both the 100 m timed test and the
2MWT may offer realistic alternatives to the longer
6MWT, especially in children with behavioural and at-
tentional problems who may find the time and testing
constraints of six minutes challenging.
The 6MWT and more recently the 100m timed test
and 2MWT, are all described as tests of physical endur-
ance in paediatric NMD and as surrogate measures of
physical fatigue in DMD, SMA and CMT [9, 25, 44].
Bartels and colleagues (2019) have recently described the
concept of fatigability in SMA, that is, “the inability to
perform prolonged repetitive tasks during activities of
daily life”, and have developed a group of endurance
tests to assess fatigability [48]. The Endurance Shuttle
Walk Test is a feasible test of endurance in ambulant
people with SMA type 3. An externally paced walking
task, the objective is to cover 10 m before each beep.
The time between repeated beeps decreases, requiring
an incremental increase in walking speed. This pilot
study is the first report of the Endurance Shuttle Walk
test and further studies are required to determine its val-
idity, responsiveness and clinical utility in SMA and
paediatric NMD.
The advent of wireless wearable activity monitors al-
lows remote measurement of gait-related physical activ-
ity in children with NMD. Several studies have included
wearable devices to measure steps and physical activity
in DMD, CMD and mixed NMD [27, 32, 53, 61]. David-
son and colleagues (2015) found that boys with DMD
have reduced daily step counts and reduced high activity
time, with correspondingly greater inactivity compared
to typically developing peers [32]. In a longitudinal
study, Fowler and colleagues (2018) described physical
activity levels in boys with DMD following a similar tra-
jectory to timed tests and the 6MWT [27]. Daily step
counts rose up to the age of 8 years, before plateauing
and declining from the age of 10 years [27]. Children
with NMD are largely inactive, spending up to 80% of
their awake time in sedentary activities and on average
only 2 h a day at a moderate intensity of activity [53, 61].
Whilst we assume neuromuscular weakness contributes
to reduced physical activity, it is quite possible that re-
duced physical activity contributes further to increasing
weakness. Lack of physical activity, together with
disease-related weakness, is likely to impact gait and
function in children with NMD.
Descriptive measures of gait
Together with quantitative measures of gait and func-
tion, descriptive scales and questionnaires are used to
characterise gait and functional ambulation in paediatric
NMD. Two such measures reported in this review are
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the Functional Mobility Scale (FMS) [67] and the Walk-
12 [68] which have not been widely utilised in paediatric
NMD to date.
The Functional Mobility Scale (FMS) is a clinical tool
used to classify typical mobility over three distance cat-
egories – 5, 50 and 500 m in children with gait dysfunc-
tion [67]. These distances are commensurate with
walking in the home (5 m), between classrooms in the
school environment (50 m) and distances required in
general community environments (500 m). The scale
considers the level of assistance the child requires and a
grading from 1 to 6 is applied; where 1 indicates the use
of a wheelchair and 6 indicates fully independent walk-
ing on all surfaces and terrains, including stairs without
use of a rail. One study has described functional mobility
in children with CMT [16]. In this study 78% of the chil-
dren reported reduced ambulatory function, across one
or all distance/environment categories (score < 6) de-
scribing the functional impact of disease. Over 12
months there was little change in FMS scores, in keeping
with the slow progression of CMT.
The Walk-12 is a self-reported questionnaire of per-
ceived impact of disease on gait and gait related activ-
ities, such as running, using stairs and balance, modified
and validated in adults with peripheral neuropathies [68,
79]. The tool is scored from 0 to 100%, where 0% indi-
cates no impact and 100% indicates a high impact of dis-
ease on gait and related activities. In two studies, Walk-
12 scores ranged from 12 to 25%, indicating that chil-
dren with CMT perceived only mild impact of disease
on gait and gait-related function [14, 22]. Interest-
ingly, further examination of answers to individual
questions indicated that CMT affected their ability to
run (43%), ascend or descend stairs (41%), the speed
with which they could walk (31%) and made it more
effortful to walk (31%) [14]. Additionally, over 40% of
the children reported moderate to severe limitations
to their ability to walk longer distances in their every-
day environments.
Clinical implications and future directions
Gait performance and functional ambulation are bio-
markers of disease severity in paediatric NMD, providing
a measure of disability. Assessment of gait and func-
tional ambulation are important outcome measures in
the toolbox of assessments for clinical research trials
and in the clinical setting. With the advent of disease-
modifying pharmacological treatments and uptake of
physiotherapeutic exercise, younger people, including
children with NMD are likely to benefit most from treat-
ments. Therefore, it is important to utilise functional
measures specific to children and adolescents to monitor
disease progression and treatment efficacy.
There remains a need for further research and devel-
opment of functional gait outcome measures for paediat-
ric NMD. Limitations including the heterogeneity of the
study populations and differences in assessment proto-
cols precluded meta-analysis of these studies. As evi-
dence accumulates, a more analytical systematic review
may provide additional insights. The disparity of gait as-
sessments in paediatric neuromuscular diseases also sug-
gests that a Delphi survey would be useful in
establishing expert consensus on which measures to use.
Factors such as the normalization of gait parameters is
important when comparing gait across age ranges and
longitudinally to account for growth in children and
should be standardly applied both clinically and in re-
search. Further development and publication of paediat-
ric normative reference datasets and MCIDs will be a
valuable resource for clinicians working in neuromuscu-
lar clinics. Qualitative characterisation of gait and func-
tional ambulation with scales or questionnaires enables
clinicians to gain an understanding of the effect of dis-
ease on the day-to-day lives of children with NMD, be-
yond the neuromuscular outpatient clinic. The self-
reported scales of functional mobility and gait-related
activities require validation in paediatric NMD popula-
tions to ensure that they provide meaningful information
and enable greater uptake by clinicians. Further explor-
ation and utilization of technology for remote and wire-
less monitoring and measurement of walking in the
typical environments of children, including home, school
and the community provide greater understanding of
the effect of disease on function.
Conclusion
This narrative review has highlighted clinical measures
of gait ranging from gait speed to tests of ambulatory
capacity, physical endurance and gait-related balance
that can be conducted in clinical and research settings
with relative ease. Consideration of environmental fac-
tors affecting function including distance requirements
necessitated by school and community settings is im-
portant when understanding the effect of disease. An in-
dividual’s perception of the effect of disease on walking
and everyday function are important considerations in
the clinical setting. Person-centred characterization and
assessment of gait dysfunction discussed in this narrative
review provides a rich and holistic illustration of disabil-
ity, and offers genuine outcome measures of potential
therapeutic benefits on gait and functional ambulation
in paediatric NMD. However, consensus is required
amongst experts in paediatric neuromuscular disorders
to establish a core set of gait and functional ambulatory
assessments that can be used clinically and in research
settings.
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